NYT: US authorities stop production of AstraZeneca at Baltimore plant

WASHINGTON, April 4 – RIA Novosti. The US authorities stopped production of the AstraZeneca vaccine at a plant in Baltimore, where a mistake in Johnson & Johnson's vaccine production resulted in the loss of 15 million doses, the New York Times reported, citing senior sources.

Biotech company Emergent BioSolution's facility will only be manufacturing a single-component vaccine from Johnson & Johnson to avoid mixing vaccine ingredients in the future, sources said.

The publication notes that the decision was made after it became known that Emergent BioSolutions, which is partnering with both companies in the production area, accidentally mixed the ingredients of two different vaccines, forcing regulators to delay the authorization of the plant's production lines.

According to the newspaper, AstraZeneca said it will work with the US administration to find an alternative production site.

Earlier, Johnson & Johnson officially confirmed the error.

Three vaccines are now approved for use in the United States: Pfizer / BioNTech, Moderna, and Johnson & Johnson. Pfizer / BioNTech and Moderna are delivering as planned. At the same time, the newspaper notes, Pfizer is even ahead of the plan, and Moderna expects permission to supply ampoules with 15 doses instead of 10.

Author: wedocount

Leave a Reply

Your email address will not be published. Required fields are marked *